# Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

> **NCT07734012** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 6 (estimated)

## Conditions studied

- Systemic Sclerosis (SSc)

## Interventions

- **DRUG:** Mycophenolate Mofetil 1000 mg twice daily

## Key facts

- **NCT ID:** NCT07734012
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734012, "Mycophenolate After Stem Cell Transplant for Systemic Sclerosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*